Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients

Hojabr Kakavand; Louise Jackett; Alexander M. Menzies; Tuba N. Gide; Matteo S. Carlino; Robyn P.M. Saw; John F. Thompson; James S. Wilmott; Georgina V. Long; Richard A Scolyer

doi:10.1038/modpathol.2017.89

Related publications

Article2017

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Preprint2023

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Tuba N. Gide, James S. Wilmott, Richard A Scolyer, Georgina V. Long

Article2021

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers, Alison M. Weppler, Allison Betof Warner, James R. Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Khang Nguyen, Lisa Zimmer, Claudia Trojaniello, Dan Stout, Megan Lyle, Oliver Klein, Camille L. Gérard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Célèste Lebbé, Paul Lorigan,

Article2019

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

Tuba N. Gide, Inês Pires da Silva, Camelia Quek, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Marcel Batten, Georgina V. Long, Richard A Scolyer, James S. Wilmott

Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients

Discussion(0)

Related publications

Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Data from Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients